Cefuroximo [INN-Spanish] en es it fr

Cefuroximo [INN-Spanish] Brand names, Cefuroximo [INN-Spanish] Analogs

Cefuroximo [INN-Spanish] Brand Names Mixture

  • No information avaliable

Cefuroximo [INN-Spanish] Chemical_Formula


Cefuroximo [INN-Spanish] RX_link


Cefuroximo [INN-Spanish] fda sheet

Cefuroximo_[INN-Spanish] FDA

Cefuroximo [INN-Spanish] msds (material safety sheet)

Cefuroximo_[INN-Spanish] MSDS

Cefuroximo [INN-Spanish] Synthesis Reference

M. C. Cook et al., U.S. Pat. 4,267,320 (1977)

Cefuroximo [INN-Spanish] Molecular Weight

424.386 g/mol

Cefuroximo [INN-Spanish] Melting Point

218-225 oC

Cefuroximo [INN-Spanish] H2O Solubility

Freely soluble as sodium salt (145 mg/L)

Cefuroximo [INN-Spanish] State


Cefuroximo [INN-Spanish] LogP


Cefuroximo [INN-Spanish] Dosage Forms

Powder; Powder for oral suspension; Tablet (125, 250, or 500 mg)

Cefuroximo [INN-Spanish] Indication

For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.

Cefuroximo [INN-Spanish] Pharmacology

Cefuroxime is a β-lactam type antibiotic. More specifically, it is a second-generation cephalosporin. Cephalosporins work the same way as penicillins: they interfere with the peptidoglycan synthesis of the bacterial wall by inhibiting the final transpeptidation needed for the cross-links. This effect is bactericidal. Cefuroxime is effective against the following organisms: Aerobic Gram-positive Microorganisms: Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes. Aerobic Gram-negative Microorganisms: Escherichia coli, Haemophilus influenzae (including beta-lactamase-producing strains), Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis (including beta-lactamase-producing strains), Neisseria gonorrhoeae (including beta-lactamase-producing strains). Spirochetes: Borrelia burgdorferi.

Cefuroximo [INN-Spanish] Absorption

Absorbed from the gastrointestinal tract. Absorption is greater when taken after food (absolute bioavailability increases from 37% to 52%).

Cefuroximo [INN-Spanish] side effects and Toxicity

Allergic reactions might be expected, including rash, nasal congestion, cough, dry throat, eye irritation, or anaphylactic shock. Overdosage of cephalosporins can cause cerebral irritation leading to convulsions.

Cefuroximo [INN-Spanish] Patient Information

Patients should be counseled that antibacterial drugs including Cefuroxime for Injection USP and Dextrose Injection USP should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Cefuroxime for Injection USP and Dextrose Injection USP is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefuroxime for Injection USP and Dextrose Injection USP or other antibacterial drugs in the future.

Cefuroximo [INN-Spanish] Organisms Affected

Enteric bacteria and other eubacteria